EdgarLookup

TENAX THERAPEUTICS, INC. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TENAX THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2015 Jan 31, 2015 $0 Mar 17, 2015
Q2 2015 Oct 31, 2014 $0 Dec 15, 2014
Q1 2015 Jul 31, 2014 $0 Sep 15, 2014
Q3 2014 Jan 31, 2014 $41.9K Mar 17, 2014
Q2 2014 Oct 31, 2013 $55.7K Dec 17, 2013
Q1 2014 Jul 31, 2013 $165.8K Sep 17, 2013
Q3 2013 Jan 31, 2013 $222.4K Mar 18, 2013
Q2 2013 Oct 31, 2012 $514.9K Dec 14, 2012
Q1 2013 Jul 31, 2012 $272.1K Sep 19, 2012
Q3 2012 Jan 31, 2012 $148.3K Mar 15, 2012
Q2 2012 Oct 31, 2011 $95.2K Dec 15, 2011
Q1 2013 Jul 31, 2011 $24.9K Sep 19, 2012
Q3 2012 Jan 31, 2011 $26.6K Mar 15, 2012
Q2 2012 Oct 31, 2010 $27.1K Dec 15, 2011

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $0 Nov 12, 2025
Q2 2025 Jun 30, 2025 $0 Aug 13, 2025
Q1 2025 Mar 31, 2025 $0 May 14, 2025

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($15.80M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($10.85M) Aug 13, 2025
Q3 2025 Jun 30, 2025 ($10.85M) Nov 12, 2025
Q2 2025 Mar 31, 2025 ($10.41M) Aug 13, 2025
Q3 2025 Mar 31, 2025 ($10.41M) Nov 12, 2025
Q1 2025 Mar 31, 2025 ($10.41M) May 14, 2025
Q3 2025 Sep 30, 2024 ($3.96M) Nov 12, 2025
Q3 2025 Jun 30, 2024 ($3.58M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($3.58M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($3.80M) May 14, 2025
Q3 2025 Mar 31, 2024 ($3.80M) Nov 12, 2025
Q2 2025 Mar 31, 2024 ($3.80M) Aug 13, 2025
Q3 2024 Sep 30, 2023 $1.97M Nov 13, 2024
Q3 2024 Jun 30, 2023 ($1.11M) Nov 13, 2024
Q2 2024 Jun 30, 2023 $1.11M Aug 13, 2024
Q3 2024 Mar 31, 2023 ($1.41M) Nov 13, 2024
Q2 2023 Mar 31, 2023 ($1.41M) Aug 14, 2023
Q1 2024 Mar 31, 2023 $1.41M May 14, 2024
Q3 2023 Sep 30, 2022 $2.92M Nov 13, 2023
Q3 2023 Jun 30, 2022 ($2.86M) Nov 13, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($16.81M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($11.79M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($11.34M) May 14, 2025
Q3 2025 Sep 30, 2024 ($4.62M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($3.67M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($3.91M) May 14, 2025
Q3 2024 Sep 30, 2023 $2.12M Nov 13, 2024
Q2 2024 Jun 30, 2023 $1.24M Aug 13, 2024
Q1 2024 Mar 31, 2023 ($1.54M) May 14, 2024
Q3 2023 Sep 30, 2022 $2.92M Nov 13, 2023
Q2 2023 Jun 30, 2022 $2.86M Aug 14, 2023
Q1 2023 Mar 31, 2022 $2.72M May 15, 2023
Q3 2022 Sep 30, 2021 $3.80M Nov 10, 2022
Q2 2022 Jun 30, 2021 $1.96M Aug 11, 2022
Q1 2022 Mar 31, 2021 $23.75M May 16, 2022
Q3 2021 Sep 30, 2020 $2.23M Nov 15, 2021
Q2 2021 Jun 30, 2020 $2.14M Aug 16, 2021
Q1 2021 Mar 31, 2020 $2.67M May 17, 2021
Q3 2020 Sep 30, 2019 $2.26M Nov 16, 2020
Q2 2020 Jun 30, 2019 $1.82M Aug 14, 2020